Clinical trials: Oral Fungal Infection
Clostridium Difficile Infection
Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123.
This is a Phase I, single center, randomized, placebo-controlled, double-blind, multiple ascending dose study to evaluate the safety and tolerability of CRS3123, a methionyl-tRNA synthetase inhibitor.
- Trial name
- NCT02106338
- Testing
- CRS3123
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Clostridium Difficile Infection Recurrence
Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff
Subjects with recurrent C. difficile infection will receive an oral dose of CP101 capsules one time in Treatment Group I or matching placebo one time in Treatment Group II.
- Trial name
- PRISM3 (NCT03110133)
- Testing
- Full Spectrum Microbiota
- Where
- 58 sites in United States, Canada
- Volunteers
- 206 people
- Sponsor
- Finch Research and Development LLC.
Gonorrhoea
A Study to Evaluate the Safety, Tolerability and Plasma PK of a Single Oral Dose of Zoliflodacin in Healthy Male and Female Volunteers
The trial is to evaluate the pharmacokinetics and safety profiles of the single-dose of zoliflodacin in eight healthy male or female subjects ages 18 to 45 years inclusive.
- Trial name
- NCT03404167
- Testing
- AZD0914
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Invasive Fungal Infections
A Bioequivalence Study of APX001 High-load and Low-load Tablets
A study to learn about the bioequivalence (the biochemical similarity of two medicines that share the same active ingredient and desired outcome for patients) of the study medicine called APX001 in healthy participants.
- Trial name
- NCT05491733
- Testing
- APX001, APX001A
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Basilea Pharmaceutica
Trisomy 8 Mosaicism, Trisomy 8 Associated Autoinflammatory Disease
Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders
Background: Trisomy 8 mosaicism is a genetic disorder that can increase inflammation in the body. Symptoms include fevers; sores or ulcers in the mouth, digestive tract, or genital area; skin rashes; problems in organs or…
- Conditions
- Trisomy 8 Mosaicism, Trisomy 8 Associated Autoinflammatory Disease, Mucosal Ulcerations
- Trial name
- NCT07683104
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Volunteer, Hidradenitis Suppurativa
A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult Volunteers
LT-002-158 is an oral IRAK4 protein degrader being developed for the treatment of autoimmune disease and inflammation including Hidradenitis Suppurativa and Atopic Dermatitis.
- Conditions
- Healthy Volunteer, Hidradenitis Suppurativa, Atopic Dermatitis
- Trial name
- NCT06082323
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Diarrhea, Cholera
Randomized Controlled Trial of Killed Oral Cholera Vaccine in Kolkata
The primary purpose of this study is to estimate the efficacy of a two-dose regimen of the oral killed bivalent cholera vaccine when administered to individual residing in a cholera-endemic area in India.
- Conditions
- Diarrhea, Cholera, Vibrio Infections
- Trial name
- NCT00289224
- Testing
- bivalent killed whole cell oral cholera vaccine
- Where
- India
- Volunteers
- 69,329 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Cholera
Evaluation of a Boosting Regimen With Oral Cholera Vaccine
Data demonstrates that Shanchol™ (killed bivalent oral cholera vaccine) provides protection over 3 years and data regarding the protective efficacy over five years is anticipated for 2012.
- Trial name
- Boost (NCT01579448)
- Testing
- Shanchol™, oral cholera vaccine, Shanchol™, killed, whole cell, bivalent, oral cholera vaccine, no intervention
- Where
- India
- Volunteers
- 426 people, healthy volunteers welcome
- Sponsor
- Sachin Desai
Trichomonas Vaginitis, Bacterial Vaginitis
Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole
This is a multi-centered, randomized, open-label, parallel, phase IV clinical trial comparing the effectiveness and cost-effectiveness of oral multi-dose metronidazole (MTZ) and oral single-dose secnidazole (SEC) for the…
- Trial name
- NCT06261840
- Testing
- Metronidazole 500 mg, Secnidazole 2000 MG
- Where
- 4 sites in United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Tulane University
Vaginal Candidiasis
Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis
Yeast vaginitis is a very common ailment affecting premenopausal women in Nigeria. This condition is more prevalent in the age group between 21-30 years.
- Trial name
- NCT00479947
- Testing
- Probiotics (Natural product), Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14)
- Where
- Nigeria
- Volunteers
- 100 people
- Sponsor
- Faith Mediplex
Multidrug Resistant Tuberculosis
Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)
The purpose of this study is to assess the efficacy, safety and tolerability of a combination of levofloxacin, linezolid, cycloserine and pyrazinamide (or clofazimine if resistant to pyrazinamide) treatments for 24 to 32 weeks…
- Trial name
- TB-TRUST (NCT03867136)
- Testing
- PZA sensitivity guided ultra-short all Oral Regimen, Standardized Shorter Regimen
- Where
- 13 sites in China
- Volunteers
- 354 people
- Sponsor
- Huashan Hospital
Tuberculosis, Multidrug-Resistant
Preventing Acquired Resistance: Strengthen TB Treatment by Adding Amikacin in the First Treatment Week of Multidrug-resistant Tuberculosis
Acquired drug-resistance is a major challenge for tuberculosis (TB) care programs. The 2020 WHO guidelines recommends replacing second-line injectables by bedaquiline in rifampicin-resistant TB (RR-TB) treatment regimens.
- Trial name
- Stake (NCT05555303)
- Testing
- Amikacin
- Where
- Rwanda
- Volunteers
- 20 people
- Sponsor
- Rwanda Biomedical Centre
Fungal Infection
A Study to Assess the Mass Balance Recovery and Metabolite Profile & Identification of [14C]-APX001 in Healthy Males
This is a single-center, open-label, non-randomized, single dose study in healthy male subjects. It was planned to enroll 2 cohorts of 5 subjects (10 subjects in total), with the target of achieving data in 4 evaluable subjects…
- Trial name
- NCT04804059
- Testing
- [14C]-APX001 Oral Solution, [14C]-APX001 Solution for Infusion
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Basilea Pharmaceutica
Tuberculosis
Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients
Primary Objective: To evaluate the effect of single and repeated administration of rifapentine given as daily or weekly regimen on steady-state pharmacokinetic parameters of efavirenz, emtricitabine and tenofovir given as a fixed…
- Trial name
- NCT01690403
- Testing
- rifapentine (M000473), EFZ EMT TDF
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sanofi
Streptococcal Infections, Pharyngitis
Treatment of Group A Beta Hemolytic Streptococcal Pharyngitis in Children in Low Resource Settings
The purpose of this study was to compare the microbiological effects of two different treatments: a single dose of intramuscular benzathine penicillin G (IM BPG) vs.
- Trial name
- TOPS (NCT01156740)
- Testing
- Penicillin G, Benzathine, Amoxicillin
- Where
- 3 sites in Brazil, Croatia and 1 more
- Volunteers
- 558 people
- Sponsor
- Johns Hopkins University
Recurrent Vulvovaginal Candidiasis
A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
VT-1161 is a novel, oral inhibitor of fungal lanosterol demethylase (CYP51). In vitro and in vivo pharmacology studies have demonstrated that VT-1161 is highly active against Candida albicans and also non-albicans Candida species…
- Trial name
- NCT02267382
- Testing
- VT-1161
- Where
- 32 sites in United States
- Volunteers
- 254 people
- Sponsor
- Viamet
Uncomplicated Urinary Tract Infections, Urinary Tract Infections
Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections
This phase 1b study is a double-blind, double-dummy, nitrofurantoin-controlled study designed to evaluate microbiological response at the test of cure (ToC) visit along with safety, tolerability and pharmacokinetic (PK) response…
- Trial name
- NCT05138822
- Testing
- GSK3882347, Nitrofurantoin
- Where
- 15 sites in United States
- Volunteers
- 140 people
- Sponsor
- GlaxoSmithKline
Failure of Dental Implant Due to Infection, Infection
Regenerative Surgical Treatment of Peri-implantitis
The purpose of the study is to evaluate if surgical treatment of peri-implantitis with enamel matrix derivative (Emdogain®, EMD) will have an additional effect on the healing outcome, changes in the peri-implant microflora and on…
- Conditions
- Failure of Dental Implant Due to Infection, Infection, Inflammation, Peri-implantitis
- Trial name
- NCT02500654
- Testing
- Emdogain®, Surgery alone
- Where
- Sweden
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Catrine Isehed
Childhood Mortality
Mortality Reduction After Oral Azithromycin: Morbidity Study
The long-term goal of this study is to more precisely define the role of mass azithromycin treatments as an intervention for reducing childhood morbidity and increasing growth, and for the potential selection of antibiotic…
- Trial name
- MORDORMorb (NCT02048007)
- Testing
- Azithromycin
- Where
- 6 sites in United States, Malawi and 3 more
- Volunteers
- 72,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Gonococcal (GC) Infection
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0914
The purpose of this study is to assess the safety and tolerability of orally administered AZD0914 in healthy adult subjects.
- Trial name
- NCT01929629
- Testing
- Part A, Part B
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- AstraZeneca